Prolactinand leptin arenewly recognised plateletco-stimulators due to potentiation of ADP-inducedp lateleta ggregation.Elevated leptin levels have recentlybeen found to be ariskfactor for ischemic strokeinboth menand women, and especiallyincombination with increasedbloodpressure forhemorrhagicstroke in men. Until nowa na ssociationb etween hyperprolactinemia and ischemic strokehas not been investigatedsystematically.We determinedplasma prolactin and leptin levels as well as platelet P-selectin expression in 36 patients with ischemic strokeo r transient ischemic attack and detectedasignificant correlation between increasedp rolactin values and enhanced ADPs timulatedP -selectin expression on platelets.I nc ontrast, no correlationofleptin valueswith plateletP-selectin expression was found.Nextwedetermined plasma prolactin and leptin as well as acquired and congenital risk factors of thrombophilia in paKeywords Platelets, CD62p,stroke, prolactin, leptin tients withf irst-evern on-hemorrhagics trokew ith or without atrial fibrillation. Excluding patients with such preexisting risk factors,21 patients withand 59 patients without atrialfibrillation were identified.Patientsw ithout atrial fibrillation revealeds ignificantlyhigher plasma prolactin levels than patients with atrial fibrillation. Furthermore, the influence of aspirin or clopidogrel on prolactin stimulatedP-selectin expression in vitro was tested, showing that aspirin was without effect,whereas clopidogrel significantly inhibitedplateletP-selectin expression.Inconclusion, hyperprolactinemia might be anovel risk factorfor strokemediating its thrombogenic effect through enhanced plateletreactivity,and this might correspond to ahigher efficacy of antiplatelet combination therapy with clopidogrelcompared to aspirin therapyalone.
Introduction
Inflammation and hypercoagulabilityare linked to the pathogenesis of atherosclerosis and its clinical manifestations suchascoronaryo rp eripheral artery disease and stroke ( 1) . Platelet activation is one of the central mechanisms in arterial thrombogenesis and in the pathophysiology of ischemic stroke (2) (3) (4) (5) . Recently, it hasbeen demonstrated thatpatients with acutecerebral ischemia have an increase of P-selectin (CD62p) on circulating platelets as amarker forplateletactivation (6) (7) (8) . CD62pserves as an adhesion receptor mediating the crosstalk between platelets ("hypercoagulability")and leukocytes or endothelia ("inflammation"). Fibrinogen, C-reactive protein (CRP)and leukocyte count are increased during stroke(9-13) and were shownto be independentlyassociatedwith the risk of first-everand recurrent vasculare vents. However, in recent studiesithas been demonstrated thatthe increase of CD62p wasregulated independentlyofthese inflammatorymarkers (7, 8) .
In apreviousstudy we identifiedprolactin(PRL)asanovel co-factor of platelet activation (14) . We demonstrated adose dependent increase of CD62p expression and increased plateletaggregation by prolactin in vivo and in vitro .Moreover,wedetected the short isoformofthe PRL-receptor on human platelets and investigated the signalling during plateletactivation with afocus on ADP-stimulatedG -protein-regulatedp athways ( 15) . In a clinical study we showeda ni ncreased incidenceo fv enous thrombembolism(VTE) in patients withprolactinoma,indicating that hyperprolactinemia maybeanimportant risk factor of hypercoagulability (15) . On the other hand,afurther hormoneleptin -h as been recentlya ssociatedw ith plateleta ctivation, suggesting amechanism of atherothrombotic diseaseinobesity or diabetes (16, 17) . Elevatedl eptin levels have recently been found to be ar isk factor fori schemic strokei nb oth men and womena nd especiallyi nc ombination with increased blood pressure for hemorrhagic strokeinmen (18, 19) . However, until nowa na ssociation between hyperprolactinemia and ischemic strokehas notbeen systematically investigated.
Therefore, we determinedplasma prolactin and leptin levels as well as CD62pexpression in patients with strokeortransient ischemic attack. Furthermore, we measured plasma prolactin and acquired and congenitalr isk factorso ft hrombophiliai na cohortof80consecutive patients with first-everstroke.
Subjects andmethods

Experimental subjects
We investigated plasma prolactin and leptin as well as CD62pex-pression in 36 patients with either ischemic strokeo rt ransient ischemic attack within 24 hours after onset of symptoms.Exclusion criteria were: infections,m alignancies, autoimmune diseases,acutecoronary syndromes, surgery withinthe last twelve months, antithrombotic therapywith coumarin, aspirin or clopidogrel and intracerebral hemorrhage. Standard diagnostic measures includedcranial computedtomographytoexclude intracerebralhemorrhage, aduplexsonographytoexclude significant stenosis of the extra-and intracerebral carotids, electrocardiogram forthe detection of arrhythmias as well as echocardiographyfor the exclusion of an intracardialthrombus. Acute cerebral ischemiaswere classified according to the TOASTcriteria (20, 21) . The control group consisted of 15 sex-and age-matched subjectswith no clinical signs of acutecoronary,peripheral,or cerebral ischemia within the 12 monthspreceding studyentrance and with acomparable atherosclerotic risk profile.
Furthermore,inaretrospectivestudy we investigated plasma prolactin in acohortof80consecutive patients with thromboembolic stroke. Blood samples were collected within 24 hours after onset of symptoms.S tandard diagnostic procedures were performedasshown above.Thrombophiliccongenital or acquired risk factorsl ikef actor VL eiden mutation, prothrombin G20210A mutation, antithrombin-, protein C-, and protein S-deficiency, activatedprotein Cresistancephenomenon, hyperhomocysteinemia, anti-phospholipid antibodies and increased factor VIII levels were excluded as previously reported (15) . Plasmaaliquots of the patients were stored at -80°Cuntil prolactin determination. No patients suffered from possible hyperprolactinemia inducing diseases like: hypothyroidism, severe renal failure, liverd isease, pituitary adenomao rr eceivedm edical therapylike: antipsychotic drugs,dopamine receptor antagonists and opiates.The local Ethics Committeeapprovedthe study.
Determinationofplasmaprolactinand leptin
The plasmaprolactinvalues of allpatients were determinedwith the Axsym Prolactin Assay(Abbott,USA). This assaywas performeda ccording to the manufacturer'si nstructions as previouslyreported (14, 15) . Theplasma leptin wasanalysed with the Human Leptin RIA Kit (Linco, USA) according to the manufacturer'sinstructions as reported elsewhere (22) .
Flowcytometric platelet analysis and platelet aggregation
The determinationo fb asal and ADP-a nd TRAP-6-stimulated CD62p expression by flow cytometryasw ellasplateletaggregation were performed as previously described (14, 15) . Based on our previous in-vivo and in-vitrostudiesweincubated platelet rich plasmaofhealthycontrols with 5,000 mU/l prolactin, which leads to maximalplateletaggregation or P-selectin expression.
Forthe investigation of prolactin effectsonADP stimulation of plateletsduring aspirin or clopidogrel therapy, citrated whole blood of healthyd onors wass timulatedw ith different concentrations of humanprolactin(Sigma,Deisenhofen, Germany) in vitro .V olunteersw ere investigated four days after oral therapy withaspirin (starting dose500 mg and further 100 mg per day) or four days after oraltherapywith clopidogrel (starting dose300 mg and further 75 mg per day).
Statisticalanalysis
The Pearson correlation coefficient wascalculated to analysethe correlation betweenprolactinorleptin and CD62pexpression in patients with strokeand controls. The Mann-Whitney-U-test was used to compare the prolactin and leptin valuesbetween the patients with strokewith and withoutembolic stroke. To investigate the influenceo fd iabetesa sapossible confounder for strokea multivariate analysis by atwo-way ANOVA test wasperformed. Moreover, we compared the prolactin valuesb etween both groups with and without diabetes. P-valueslessthan 0.05 were considered as statistically significant. Data were analysed with SPSSfor Windows (released9.0.1).
Results
Correlation between ADP-stimulatedCD62p expressionand plasma prolactinlevels in patients with stroke or transientischemicattack Patients with ischemic strokeortransient ischemic attack revealed significantlyh igherA DP-stimulated CD62pe xpression (p<0.001) and prolactin values(p<0.001) than the healthycontrols. In contrast, no significant difference wasdetected forleptin levels (Table 1) .Inpatients with ischemic strokeortransient ischemic attack, prolactin valueswere well correlated with ADPstimulatedC D62p expression (r=0.56; p<0.0001; Fig. 1A ), whereas no significant correlation wasfound with plasma leptin (Fig. 1B) . Furthermore,wedetected no differences eitherinPRL valuesorinCD62p expression betweenpatients with strokeand transient ischemic attack. CD62p expression of TRAP-6 stimulated and non-stimulatedplatelets wasneitherinfluencedbyprolactin nor leptin (datanot shown).
Prolactinvalues in patients with ischemicstroke without embolism aresignificantlyhigherthan in patients with embolic stroke by atrial fibrillation
We identified 21 patients (nine female,12male; age: 72.9 ±9.3, range 50-87 years) with thromboembolics troke by atrial fibrillation and59patients (28 female,31male; age: 62.3 ±15, range 28-88 years) without embolism.Therefore,patients with atrial fibrillation showed asignificant tendencyfor higherage (p=0.004) without significant(p=0.08) differences in sexdistribution. Allpa-tients were freeofsevereaccompanying diseases. Frequenceofhyperlipidemiaw as not different between patients with (twoo f2 1) andwithout (fiveof59) atrial fibrillation (p=0.88). Moreover,there were no significantdifferencesfor smoking (one of 21 vs.10of59; p=0.27) or hypertension(nine of 21 vs.25of59; p=0.96) between strokepatients with or without atrial fibrillation. Patients with atrial fibrillation showed ahigher frequencyofdiabetes(nine of 21 vs. eight of 59) thanpatients without atrial fibrillation (p=0.004).
In 21 patients with embolic strokeb ya trialfibrillation the mean value of prolactin was142.3 ±50.8 mU/l, whereas in 59 patients without embolic stroke, the mean prolactin value was significantlyhigher(268.1 ±336.4 mU/l; p=0.005; Fig. 2 ). Furthermore,ineight of the patients without embolic stroke, the prolactin valuesw ere above the calculated maximum of the group (prolactin levels between 471and 2,597 mU/l; dots in Fig. 2) .
To investigate the possibleinfluenceofdiabetesasapossible confounderf or stroke, am ultivariate analysis by at wo-way ANOVA testwas performed. Patients with prolactin values >700 mU/l were excludedfrom this analysis. Thesignificant (p=0.002) differences in prolactinv alues between both groups were independent of diabetes.M oreover,w ed etected significantd ifferences (p=0.003) in prolactin values betweenb oth groups when patients with diabetes were excluded, whereas no differences (p=0.122) in prolactin were found between patients with diabetes.
Influence of aspirinorclopidogrel on prolactin stimulated CD62p expression
Next we investigated the influenceofaspirin or clopidogrel on prolactin stimulatedCD62p expression in vivo .After treatment, aspirinshowednoeffect on prolactin enhanced ADP-stimulated CD62pexpression, whereas oral clopidogrel treatment resulted in inhibition of prolactin enhanced ADP-stimulatedC D62 expression in all investigated individuals ( Fig. 3) . Furthermore, clopidogrel completelyi nhibited prolactin-induced enhancement of plateletaggregation (Fig. 4) .
Discussion
Plateleta ctivation is ac rucial mechanism in arterial thrombogenesis and in the pathogenesis of ischemic stroke. An increase of plateletactivation markers such as CD62pduring strokehas been reportedand supports this concept (8) .T othe best of our knowledge,our study is the first oneinvestigating in parallel prolactin valuesand ADP-stimulatedCD62p expression on platelets in patients with strokeortransient ischemic attack. We found increased levels of CD62p expression in patients with ischemic strokeortransient ischemic attack (Table 1) ,comparable to previous reports (8) .W ed etected significantlyh igherp rolactin valuesinpatients with ischemic strokeortransient ischemic attack thani nm atched healthyc ontrols (Table 1 ). However, in these patients no difference wasfound in leptin levels compared to matchedcontrols. In patients with strokeortransient ischemic attack, the ADP-stimulatedC D62p expression correlated significantlyw ith plasma prolactin levels corresponding to previousfindings thatdemonstrate astronger effect on platelet activation by prolactin comparedwith leptin in vitro and in vivo (22) . Finally, clopidogrel butnot ASS wasdemonstrated to efficiently block prolactin-induced plateletactivation.
Up to nowa na ssociation between hyperprolactinemia and strokehas notbeen investigated. However, it is widelyaccepted thatthe risk of strokeishighlyincreased twodaysprior to giving birth and during the first sixweeks postpartum (23) .Inparallel, prolactin hasapredominant increase around delivery and during the first time of lactation (24, 25) . Therefore, an association be- tweenstrokeand prolactine increase at delivery and during lactation can be assumedbut has not beeninvestigated so far.
Moreover, pituitaryapoplexy is associated with prolactinoma or hormone inactive macroadenoma, especially during TRH stimulation test (26, 27) . In our previous paperw ew ere able to demonstratet hat prolactin and P-selectin showedap arallel short-term increase after TRHi njection (14) .T herefore,w e speculatet hat the prolactin increase after TRH stimulation in hormone inactive macroadenomam ight be triggering pituitary apoplexyvia plateletactivation.
Arecent study demonstrated an association between atherosclerotic diseases likestrokeand spontaneous venous thrombosis (28) .This association wasstill present after adjustment for typical risk factorsfor atherosclerosis and thrombophilic conditions. Therefore, this study implies either that atherosclerosis caninduce VTE or that both conditions sharethe same,presentlyunknown, risk factors ( 28) . Hyperhomocysteinemia, factor V Leiden, and lupus anticoagulant have beensuggestedaspotential risk factorsfor atherosclerosis and VTE (29) (30) (31) .Inboth diseases increased fibrin turnoveraswellasanactivation of blood coagulation, especiallyo fp latelets, is detectable (32) (33) (34) (35) (36) (37) (38) . The participation of platelets in the pathogenesis of chronic atherosclerotic lesions and acute thromboticocclusion of arteries is undisputed. This effect is due to plateleta dhesive propertiesa nd their ability to respond to stimuli with rapid activation (39) .
In previousstudieswehavedemonstrated thatpatients with venous thrombembolism (VTE) without congenital or acquired risk factorshad significantlyhigherprolactinlevelsthan those with congenital risk factorso rh ealthyc ontrols. On the other hand,patients with prolactinoma hadasignificantly higher incidenceo fi diopathic VTE than the generalp opulation (15) .I nflammation and thrombosis arei ntimately connected as stated above.However,until nowthe significance of activatedplatelets for the development of VTEisnot systematicallyinvestigated. Beyond the well-known plasmatic factors, the pathogenesis of VTEinvolves complexplatelet-leukocyte-interactionswhereby details arenot fullyelucidated (40) . P-selectin mediatesrolling of platelets and leukocytes on activatedendothelial cells.Recent dataindicate that P-selectin interaction with aligand stabilizes initialG PI Ib/IIIa-fibrinogen interactions, thus allowing the formation of large stable plateletaggregates (41) . Furthermore, in the Pulmonary Embolism Prevention Trial( PEP) it wasd emonstrated thata spirin can reduce VTEb ya tl eastathird throughoutaperiod of increased risk (42) .These results, along with those of apreviousmeta-analysis (43, 44) , suggest that the activation of platelets is an important initialstepinthe development of VTE. Therefore, ourfindings indicated thath yperprolactinemia might be involved in venous and arterial thrombotic disease and that it mediatesits thrombogenic effectsthrough enhanced plateletreactivity.
Therefore,weevaluatedthe prolactin valuesinpatients without congenital or acquiredthrombophilicrisk factorssimilarto our previous study on VTE (15) .Patients without embolic stroke showedsignificantly higher plasma prolactin levels compared to patients with embolic strokebyatrialfibrillation (Fig. 2) .Most of the patients with strokewithoutatrialfibrillation hadprolactin valuesthat were still in the upper normal range. This finding corresponds to the dose-dependent increase of plateletactivation and aggregation by human prolactin in vitro thatoccursalready within the normalplasma prolactin range (14, 15) . We detected no association betweenp rolactinv alues and platelet counts eitherinpatients with strokeorinour previous studies (14, 15, 22) . This fact can be confirmed by other studies investigating the effect of dopamine or dopamine antagonists on prolactin values and platelet countsinparallel (45) .
In univariate analysis possible confoundersfor strokeashypertension, hyperlipidemia and smoking have beene xcluded. However, patients with atrial fibrillation showedhigherfrequency of diabetes, whichhas been demonstrated as an important risk factor forthromboembolicstroke (46) . In our multivariate analysisweconfirmed differencesinprolactinvalues independent of diabetes.
Ther esults of our studya re limitedb yp rolactind etermination at the acutestage of strokeand the lackofanalysis of an association betweenstrokeseverity and prolactin. Indeed it is uncertain if prolactin levels were increased before stroke, and whether prolactin is triggering or enhancing platelet activation in stroke. However, in our present study we showedanassociation between increased prolactin valuesa nd plateleta ctivation measured by P-selectin expression, whichi so ne of the central mechanisms in arterial thrombogenesis and in the pathophysiologyofischemic strokeasstatedabove.Therefore,weconclude that increased prolactin valuesmight be involved in plateletactivation during stroke.
Oneo ft he most likelye xplanations for increased prolactin valuesi np atients with strokem ight be stress. It is widely accepted thatp rolactinl evelsc an be increased by stress factors suchaspain (47, 48) . However, we detectednodifferences either in PRL valueso ri nC D62p expression betweenp atients with strokeand transient ischemic attackinour cohortof36patients, indicating no correlation between severity/duration of ischemia and PRL levels. Probably, there are no differences in stressbetween both groups of patients. However, patients with stroke withoutatrialfibrillation showedsignificantly higher prolactin valuesthan patients with atrial fibrillation. Therefore, the cause of higher prolactin valuesinpatients without atrial fibrillation is unknown. Against the background of the association between prolactin increase and plateletactivation the courseofprolactin increase might be of minor importanceand seems to be speculative at the moment. However, in ap reviouss tudy increased nocturnal prolactin valueswere observed in patients after stroke compared with healthyvolunteers, whereas the rhythm of cortisol wasu ndisturbed ( 49) . This study implies al ong-term elevation of prolactin in patients with stroke. Unfortunately,wehave no prospective data on our patients yet. Altogether, our previous epidemiological datainprolactinoma or in patients with idiopathicVTE (15) as well as ourpresent results suggest thathyperprolactinemia might be acandidate for an ovel acquired risk factor forv enous as well as fora rterial thrombogenesis by enhancing platelet activation and aggregation.
Several antiplateleta gents with different pharmacological mechanisms are currentlyavailablefor secondaryprevention of ischemic stroke. Aspirin is the best studied and most widelyused antiplatelettherapyfor strokeprevention. In acute coronarysyndrome without ST-segment elevation, the CURE studyshoweda 20% relative risk reduction of cardiovascular deathoranabsolute benefito f2 .1% for combination therapyw ith clopidogrel and aspirinthan for aspirin alone (50) .Becauseofthe substantial differencesb etween cerebrovasculara nd cardiacp atients the CURE data can notbeextrapolated to cerebrovascularpatients. Recently,the MATCH study addressedthis question (51) .This trial comparedt he combination of aspirin/clopidogrel with clopidogrel aloneinhigh risk patients with arecent stroke/TIA. In MATCH, the combination of the twoantiplatelet agents prevented slightlymore strokes, butthis effect did not reachstatistical significance. However, these major vascularevents areonly one aspect of plateletfunction in stroke. Platelet attachment to endothelium,mediated by plateletP-selectin, might lead to inflammatory reactionsp romoting endotheliald ysfunction and long-termc ardiovascularc omplications (52).T herefore,c ombining twoanti-plateletagents might indeedprovide major advantagesinthe long run.
Our ex-vivo /in-vitro studies demonstrated that aspirin was withoute ffect on prolactin-enhanced ADP-stimulatedC D62p expression (data not shown),a sd ocumented previouslyi np atients with acutecoronary syndrome (53).Incontrast, clopidogrel showedasignificant inhibition of prolactin enhanced ADPstimulatedCD62p expression (Fig. 3) . Our findings reconciled a previous study demonstrating an inhibition of ADP-stimulated CD62pbyclopidogrel (54) . This result wasexpected by our previous studies of the molecularmechanism of plateletactivation by PRL.The stimulating effect of prolactin on plateletactivation by CD62pe xpression and aggregation depends on ac o-activation with ADP (14, 15) , and clopidogrel is aspecific inhibitor of ADP-receptor P2Y 12 ,whereasASS actsoncyclooxygenase-1, herebyb locking thromboxane As ynthesis (39) .Therefore,o ur present in-vitro data might be afacet to explain the higher efficacyofantiplatelet combination therapywith clopidogrel compared to aspirin therapyalone in arterial thrombogenesis, as suggested by the CURE study (50) . In conclusion, our study demonstratesthat prolactin butnot leptin did correlate to plateletactivation in patients with stroke.
In summary, hyperprolactinemia might be anovel risk factor forstrokemediating its thrombogenic effect throughenhanced plateletreactivity,and this finding might supportthe higher efficacyofantiplatelet combination therapywith clopidogrel and aspirin than aspirin therapyalone.
